The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Miles Prince
Executive Steering Committee Member
Professor Miles Prince is the Director of the Centre for Blood Cell Therapies at the Peter MacCallum Cancer Centre, Melbourne, AU, Director of Molecular Oncology and Cancer Immunology at Epworth Hospital, Melbourne, AU, as well as Professor at both University of Melbourne and Monash University, Melbourne, AU. Prof. Prince obtained a BSc in Medicine (Hons), a BSc in Surgery (Hons), and a Doctor of Medicine from Monash University. He trained in Melbourne, Sydney, AU and Toronto, CN.
Prof. Prince treats all types of blood disorders, including anemia, blood clots, and all blood-related cancers. He runs an active research group in stem cell research for the development of and better understanding of the role of the immune system in blood cancer development. In 1995, he set up the Centre for Blood Cell Therapies at Peter MacCallum Cancer Centre, which includes GMP laboratories for cell-based therapies including CAR T-cell protocols. His clinical research focuses on myeloma, T-cell lymphoma, and immune-based therapies.
Positions of responsibility/awards:
- Published more than 300 articles in peer-reviewed journals and is a member of several international hematological societies, including the Haematology Society of Australia and New Zealand, the American Society of Hematology, and the European Hematology Association
- Member of the Board of the International Society of Cutaneous Lymphomas, the International Waldenstrom's Macroglobulinemia Foundation (IWMF) and Chairman of the Medical Scientific & Advisory Group (MSAG) of Myeloma Australia
- Awarded Member of the Order of Australia (general division) in 2014 for significant services to blood cancer research, patient care, and philanthropic leadership
Steering committee member of Multiple Myeloma Hub
Filter by content: